RxDoctor Payments Data

Todd Tessendorf, MD

Cardiovascular Disease · Lincoln, NENPI 1730139502

Payments from drug & device makers

$1,170in general payments, 2019–2025

Across 74 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$186
  • Pfizer$132
  • Medtronic$131
  • Boehringer Ingelheim$124
  • Amgen$115
  • Johnson & Johnson$107
  • plus $376 from 8 others

What the payments were for

  • Food & beverage$1,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,170 in reported general payments places this provider in the 30th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$289,104
Medicare patients
2,093
Services billed
3,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban485$418,363
XareltoRivaroxaban184$178,374
Repatha SureclickEvolocumab113$72,973
EntrestoSacubitril/Valsartan47$33,916
JardianceEmpagliflozin32$22,776
MultaqDronedarone Hcl22$18,558
Praluent PenAlirocumab15$16,707
Ranolazine ErRanolazine128$7,856
Repatha SyringeEvolocumab14$7,399
Flecainide Acetate91$7,382
Metoprolol Succinate597$6,781
Nebivolol Hcl129$5,727
Midodrine Hcl57$4,515
Potassium Chloride179$4,254
Droxidopa17$3,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$418,363485 claims
Johnson & JohnsonXarelto$107$178,374184 claims
NovartisEntresto$186$33,91647 claims
Boehringer IngelheimJardiance$124$22,77632 claims
Sanofi-aventis U.S. LLCMultaq$95$18,55822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →